5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) – Pipeline Review, H1 2018

Global Markets Direct’s, ‘5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) – Pipeline Review, H1 2018’, provides in depth analysis on 5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in 5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) targeted therapeutics development and features dormant and discontinued projects. The report analyses the pipeline products from therapy areas Central Nervous System, Cardiovascular, Genetic Disorders and Respiratory under development targeting 5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7).

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.

Scope

– The report provides a snapshot of the global therapeutic landscape for 5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7)

– The report reviews 5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved in 5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) targeted therapeutics and enlists all their major and minor projects

– The report assesses 5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news and deals related to 5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for 5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding 5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

Adamed Sp z oo

Astellas Pharma Inc

H. Lundbeck AS

Johnson & Johnson

Reviva Pharmaceuticals Inc

Sumitomo Chemical Co Ltd

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) Overview 7

5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) Therapeutics Development 8

Products under Development by Stage of Development 8

Products under Development by Therapy Area 9

Products under Development by Indication 10

Products under Development by Companies 12

Products under Development by Universities/Institutes 15

5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) Therapeutics Assessment 17

Assessment by Mechanism of Action 17

Assessment by Route of Administration 19

Assessment by Molecule Type 21

5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) Companies Involved in Therapeutics Development 22

Adamed Sp z oo 22

Astellas Pharma Inc 22

H. Lundbeck AS 22

Johnson & Johnson 23

Reviva Pharmaceuticals Inc 23

Sumitomo Chemical Co Ltd 24

5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) Drug Profiles 25

ADN-1184 Drug Profile 25

Product Description 25

Mechanism Of Action 25

R&D Progress 25

ADN-3662 Drug Profile 26

Product Description 26

Mechanism Of Action 26

R&D Progress 26

DDD-028 Drug Profile 27

Product Description 27

Mechanism Of Action 27

R&D Progress 27

JNJ-18038683 Drug Profile 28

Product Description 28

Mechanism Of Action 28

R&D Progress 28

lurasidone hydrochloride Drug Profile 29

Product Description 29

Mechanism Of Action 29

R&D Progress 29

RP-5063 Drug Profile 41

Product Description 41

Mechanism Of Action 41

R&D Progress 41

SERx-519 Drug Profile 44

Product Description 44

Mechanism Of Action 44

R&D Progress 44

Small Molecule to Agonize Alpha 2 Adrenergic Receptor and Antagonize 5-HT7 and 5-HT5A Receptors for Psychiatric Disorders Drug Profile 45

Product Description 45

Mechanism Of Action 45

R&D Progress 45

Small Molecules to Inhibit 5-HT2B and 5-HT7 Receptors for Migraine Drug Profile 46

Product Description 46

Mechanism Of Action 46

R&D Progress 46

vortioxetine hydrobromide Drug Profile 47

Product Description 47

Mechanism Of Action 47

R&D Progress 47

5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) Dormant Products 53

5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) Discontinued Products 54

5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) Product Development Milestones 55

Featured News & Press Releases 55

Apr 20, 2018: Sunovion Announces Health Canada Approval of Latuda (lurasidone HCl) to Treat Adolescents (13 to 17 years of age) with Bipolar Depression 55

Apr 18, 2018: Sumitomo Dainippon Pharma Announces U.S. Appellate Court Decision on Substance Patent Infringement Lawsuit Regarding LATUDA 55

Apr 10, 2018: Reviva Pharmaceuticals Receives FDA Orphan Designation for RP5063 for the Treatment of Idiopathic Pulmonary Fibrosis (IPF) 56

Mar 06, 2018: Sunovion Receives FDA Approval of Supplemental New Drug Application (sNDA) for Use of Latuda (lurasidone HCl) in the Treatment of Bipolar Depression in Pediatric Patients (10 to 17 Years of Age) 57

Feb 23, 2018: Sumitomo Dainippon Pharma Filed Patent Infringement Lawsuits Regarding LATUDA in US 57

Feb 14, 2018: Sumitomo Dainippon Pharma Filed Patent Infringement Lawsuits Regarding LATUDA in the United States 58

Dec 04, 2017: Lundbeck’s Brintellix approved in China 58

Oct 27, 2017: Sunovion Presents Data from Phase 3 Studies of Latuda (lurasidone HCl) in Children and Adolescents with Bipolar Depression 59

Oct 17, 2017: Reviva Pharmaceuticals Announces Successful Completion of Pre-IND Meeting With FDA on RP5063 for the Treatment of Pulmonary Arterial Hypertension 61

Sep 14, 2017: Sunovion to Present Data on LATUDA at the 2017 Psych Congress 61

Jul 21, 2017: Sunovion’s Latuda (lurasidone HCI) Receives Health Canada Approval to Treat Adolescents with Schizophrenia 62

Jun 30, 2017: Sunovion Announces FDA Acceptance for Review of Supplemental New Drug Application for Latuda for the Treatment of Bipolar Depression in Children and Adolescents 62

Jun 23, 2017: Lundbeck and Takeda receive Complete Response Letter from the FDA for Trintellix (vortioxetine) sNDA 63

Jun 23, 2017: Lundbeck and Takeda receive Complete Response Letter from the FDA for Trintellix sNDA 63

Jun 09, 2017: Sumitomo Dainippon Pharma Announces Topline Results from a Phase 3 Study of Lurasidone, an Atypical Antipsychotic Agent, in the Treatment of Patients with Bipolar l Depression 64

Appendix 65

Methodology 65

Coverage 65

Secondary Research 65

Primary Research 65

Expert Panel Validation 65

Contact Us 65

Disclaimer 66

List of Tables

List of Tables

Number of Products under Development by Stage of Development, H1 2018 8

Number of Products under Development by Therapy Areas, H1 2018 9

Number of Products under Development by Indication, H1 2018 11

Number of Products under Development by Companies, H1 2018 12

Products under Development by Companies, H1 2018 13

Products under Development by Companies, H1 2018 (Contd..1), H1 2018 14

Number of Products under Investigation by Universities/Institutes, H1 2018 15

Products under Investigation by Universities/Institutes, H1 2018 16

Number of Products by Stage and Mechanism of Actions, H1 2018 18

Number of Products by Stage and Route of Administration, H1 2018 20

Number of Products by Stage and Molecule Type, H1 2018 21

Pipeline by Adamed Sp z oo, H1 2018 22

Pipeline by Astellas Pharma Inc, H1 2018 22

Pipeline by H. Lundbeck AS, H1 2018 23

Pipeline by Johnson & Johnson, H1 2018 23

Pipeline by Reviva Pharmaceuticals Inc, H1 2018 24

Pipeline by Sumitomo Chemical Co Ltd, H1 2018 24

Dormant Projects, H1 2018 53

Discontinued Products, H1 2018 54

List of Figures

List of Figures

Number of Products under Development by Stage of Development, H1 2018 8

Number of Products under Development by Therapy Areas, H1 2018 9

Number of Products under Development by Top 10 Indications, H1 2018 10

Number of Products by Mechanism of Actions, H1 2018 17

Number of Products by Stage and Mechanism of Actions, H1 2018 17

Number of Products by Routes of Administration, H1 2018 19

Number of Products by Stage and Routes of Administration, H1 2018 19

Number of Products by Stage and Molecule Type, H1 2018 21

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports